Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.63 |
| ▸ | PGR | P06401 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.53 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803295 | 0.80 | CNR2 (0.59) | NR3C1PGRALDH1A1LMNANPSR1 | |
| SCHEMBL6962920 | 0.80 | NR3C1 (0.68) | NR3C1PGRALDH1A1LMNANPSR1 | |
| SCHEMBL14470046 | 0.79 | KMT2A (0.56) | NR3C1PGRALDH1A1LMNANPSR1 | |
| SCHEMBL6799209 | 0.78 | MAPT (0.52) | ALDH1A1KEAP1NFE2L2MEN1KMT2A | |
| SCHEMBL6865614 | 0.77 | ALDH1A1 (0.64) | NR3C1PGRALDH1A1LMNANPSR1 | |
| SCHEMBL6806676 | 0.76 | HIF1A (0.55) | NR3C1PGRALDH1A1LMNANPSR1 | |
| SCHEMBL7420825 | 0.76 | PDE4D (0.62) | HIF1AEPAS1EP300TAS2R14MAPT | |
| SCHEMBL398861 | 0.75 | KEAP1 (0.70) | KEAP1NFE2L2MEN1KMT2AMAPT | |
| SCHEMBL2192252 | 0.75 | LMNA (0.71) | NR3C1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3380874 | 0.74 | NR3C1 (0.54) | NR3C1KEAP1NFE2L2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | claimed |
| US-6743787-B2 | FOR THERAPY OF METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA IN A MAMMAL | WYETH | 2004-06-01 | — | — | US | disclosed |
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | WYETH | 2003-02-06 | — | — | US | disclosed |
| US-6444685-B1 | THERAPY FOR METABOLISM DISEASES; DIETETICS; ANTIDIABETIC AGENTS | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-07 | — | — | US | disclosed |
| WO-2002006274-A1 | N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | NR3C1 142/4885PGR 3274/4885ALDH1A1 2253/4885 |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | NR3C1 157/4885PGR 3399/4885ALDH1A1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.